Natalie Schub

Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Nico Gagelmann, Danai Dima, Maximilian Merz et al. · Journal of Clinical Oncology · 2024 · 83 citations · Full text

Medicine, Immunology, Oncology +17

MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial

Marc S. Raab, Monika Engelhardt, Antje Blank et al. · The Lancet Haematology · 2020 · 79 citations

Medicine, Hematology, Oncology +14

Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective

Natalie Schub, Andreas Günther, André Schrauder et al. · Bone Marrow Transplantation · 2010 · 71 citations

Life Sciences, Clinical Sciences, Immunology +11

Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients

Stefan Langner, Philipp B. Staber, Natalie Schub et al. · Bone Marrow Transplantation · 2008 · 63 citations

Dentistry, Oral Health Sciences, Oral Medicine +10

Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial

Marc S. Raab, Niels Weinhold, K. Martin Kortüm et al. · Blood · 2024 · 40 citations

Medicine, Immunology, Oncology +15